The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Estimated Growth In Market Size Of The Pergoveris Market During 2026–2030?
Historical expansion stemmed from a surge in gonadotropin deficiency diagnoses, the proliferation of assisted reproductive clinics, improved success rates for IVF treatments, the accessibility of recombinant hormone technologies, and heightened awareness surrounding infertility.
The anticipated expansion during the forecast period is primarily driven by the escalating demand for advanced IVF protocols, a heightened focus on personalized hormone therapy, the continued growth of fertility tourism, increasing acceptance of user-friendly injectable formats, and rising investments in reproductive biotechnology. Prominent trends observed throughout this period encompass the greater adoption of recombinant hormone therapies, an increasing need for IVF and other assisted reproductive technology procedures, the expanding application of injectable pen formulations, the proliferation of precisely controlled fertility treatments, and an elevated emphasis on addressing hormone deficiencies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20181&type=smp
What Key Growth Drivers Are Influencing The Pergoveris Market?
The growing occurrence of infertility is projected to propel the pergoveris market’s expansion moving forward. Infertility describes the inability to become pregnant, sustain a pregnancy, or complete a full term. This rise in infertility is attributed to various elements including postponed childbearing, lifestyle decisions, environmental pollutants, and the increasing incidence of medical conditions like polycystic ovary syndrome (PCOS) and endometriosis. Pergoveris assists individuals experiencing infertility by stimulating ovarian activity through a blend of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby fostering egg development in women with significant gonadotropin deficiency. For example, in April 2023, the World Health Organization, a Switzerland-based intergovernmental body, reported that roughly 17.5% of the worldwide adult population, equivalent to about 1 in 6 people, struggles with infertility. Consequently, the increasing prevalence of infertility is accelerating the pergoveris market’s development.
What Segment Types Are Included In The Pergoveris Market Analysis?
The pergoveris market covered in this report is segmented –
1) By Formulation: Injectable Pen, Vial Formulation
2) By Indication: Anovulation, Assisted Reproductive Technology (ART) Procedures
3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Which Trends Are Supporting The Evolution Of The Pergoveris Market?
Leading companies in the pergoveris market are concentrating on developing regulatory and access-focused advancements, such as priority-review filings under the FDA Commissioner’s National Priority Voucher (CNPV) program. This focus aims to reduce approval timelines, expand patient access, and improve the affordability of complex fertility therapies. A priority-review filing enables regulators to shorten the standard 10–12 month review period to just 1–2 months, thereby allowing for the quicker availability of innovative reproductive treatments while ensuring their safety and efficacy. For instance, in October 2025, EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, submitted Pergoveris® under the FDA CNPV program. This therapy combines recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) in a 2:1 ratio, delivered via a pre-filled Redi-ject® pen to simplify dosing, minimize injections, and enhance the overall patient experience. Pergoveris is designed to mirror natural reproductive physiology, supporting follicular development and maturation in medically assisted reproductive cycles. The program also aligns with public-private partnerships and direct-to-consumer access initiatives, ultimately improving affordability and expanding treatment options for women facing severe FSH/LH deficiency.
Which Companies Are Influencing The Pergoveris Market?
Major companies operating in the pergoveris market are Merck KGaA
Access The Complete Pergoveris Market Report:
https://www.thebusinessresearchcompany.com/report/pergoveris-global-market-report
What Is The Largest Regional Market In The Pergoveris Market?
Europe was the largest region in the pergoveris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pergoveris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model